EUVIMEDEUVIMED entdecken
Open Access

The prognostic impact of CDKN2A/B hemizygous deletions in IDH-mutant glioma

Franziska M Ippen, Thomas Hielscher, Dennis Friedel, Kirsten Göbel, David Reuss iD, Christel Herold-Mende, Sandro Krieg, Andreas V Deimling, Wolfgang Wick iD, Felix Sahm iD, Abigail K Suwala iD

Neuro-Oncology · 07.03.2025 · 27 (3) · 743-754

DOI: 10.1093/neuonc/noae238 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 12.11.2024. Verfasst von Franziska M Ippen und 10 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ and University Hospital Heidelberg, Heidelberg, Germany. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase Inhibitor p16, Brain Neoplasms, Cyclin-Dependent Kinase Inhibitor p15, Isocitrate Dehydrogenase. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Center for Tumor Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Homozygous deletions of CDKN2A/B are known to predict poor prognosis in gliomas, but the impact of hemizygous deletions is less clear. This study aimed to evaluate the prognostic significance of hemizygous CDKN2A/B deletions in IDH-mutant low-grade astrocytomas and oligodendrogliomas.

Methods

Tissue samples diagnosed as astrocytoma, IDH-mutant and oligodendroglioma, IDH-mutant, 1p/19q co-deleted CNS WHO grade 2 and 3 were collected from the archives of the Institute of Neuropathology in Heidelberg. DNA methylation analysis was performed on formalin-fixed paraffin-embedded samples. Evaluation of the CDKN2A/B locus was performed by visual inspection of copy-number plots derived from methylation-array data for each case. Hemizygous and homozygous losses were assessed in relation to whole chromosomal or larger segmental losses and gains in the chromosomal profile. Survival probabilities were assessed using the Kaplan–Meier method.

Results

A total of 334 low-grade glioma cases were identified, including 173 astrocytomas and 161 oligodendrogliomas. Hemizygous deletions in CDKN2A/B (37/173 in astrocytomas, 15/161 in oligodendrogliomas) did not confer significantly worse survival outcomes compared to CDKN2A/B wild-type cases in neither low-grade astrocytoma (log-rank P = .2556; HR 2.29, 95% CI [0.76; 6.40], P = .135) nor oligodendroglioma (log-rank P = .2760; HR 0.17; 95% CI [0.01; 5.05]; P = .305), regardless of CNS WHO grade, which was further demonstrated on a subgroup of astrocytoma, IDH mutant CNS WHO 4 cases (log-rank P = .1680; HR 4.55, 95% CI [0.88; 24.51], P = .0689).

Conclusions

Hemizygous CDKN2A/B deletions do not significantly worsen OS or progression-free survival in IDH-mutant astrocytomas and oligodendrogliomas, CNS WHO grades 2 and 3.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin-Dependent Kinase Inhibitor p16Brain NeoplasmsCyclin-Dependent Kinase Inhibitor p15Isocitrate DehydrogenaseMutationGliomaOligodendrogliomaBiomarkers, TumorHumansFemaleMalePrognosisMiddle AgedAdultDNA MethylationAgedSurvival RateYoung AdultFollow-Up StudiesAdolescentGene DeletionAstrocytoma

Stichwörter der Autor:innen

CDKN2A/BIDH-mutant gliomahemizygous deletionsurvival

Substanzen

Cyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p15Isocitrate DehydrogenaseCDKN2B protein, humanCDKN2A protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • National Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ and University Hospital Heidelberg, Heidelberg, Germany.
  • Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.
  • Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany.
  • Department of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Faculty of Bioscience, Heidelberg University, Heidelberg, Germany.
  • Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany.

ORCID-Profile: David Reuss, Wolfgang Wick, Felix Sahm, Abigail K Suwala

Förderung

  • National Center for Tumor Diseases

Zitieren

APA

Ippen, F. M., Hielscher, T., Friedel, D., Göbel, K., Reuss, D., Herold-Mende, C., Krieg, S., Deimling, A. V., Wick, W., Sahm, F., & Suwala, A. K. (2025). The prognostic impact of CDKN2A/B hemizygous deletions in IDH-mutant glioma. Neuro-Oncology, 27(3), 743-754. https://doi.org/10.1093/neuonc/noae238

Vancouver

Ippen FM, Hielscher T, Friedel D, Göbel K, Reuss D, Herold-Mende C, et al. The prognostic impact of CDKN2A/B hemizygous deletions in IDH-mutant glioma. Neuro-Oncology. 2025;27(3):743-754. doi:10.1093/neuonc/noae238

BibTeX
@article{Ippen2025,
  author = {Ippen, Franziska M and Hielscher, Thomas and Friedel, Dennis and Göbel, Kirsten and Reuss, David and Herold-Mende, Christel and Krieg, Sandro and Deimling, Andreas V and Wick, Wolfgang and Sahm, Felix and Suwala, Abigail K},
  title = {The prognostic impact of CDKN2A/B hemizygous deletions in IDH-mutant glioma},
  journal = {Neuro-Oncology},
  year = {2025},
  volume = {27},
  number = {3},
  pages = {743--754},
  doi = {10.1093/neuonc/noae238}
}
Kostenlos starten →